Overcoming the challenges in the pharma/biotech industry.
In the face of patent expirations at a time of declining innovation across the industry, companies are restructuring their research and development operations and are pursuing an aggressive strategy of acquisitions, licensing deals and research collaborations to boost their drug pipelines.